Email not displaying correctly? View content online | Foward to a friend
Latest from GlobalData   September 2018

Spotlight Media Updates

more >
With Alzheimer’s treatment stalled, promising pipeline drugs and a shift in perception could be key to tackling the disease, says GlobalData

As World Alzheimer’s Day approaches (21 September) with the aim of raising global awareness and understanding of the issues faced by people affected by dementia it’s timely to reflect that no new drug for Alzheimer’s disease (AD) has been approved in the past 16 years, despite more than 400 clinical trials and billions of dollars...

Number of respiratory conditions will continue to rise if UK air pollution goes unchecked, says GlobalData

The number of people suffering from respiratory indications and the severity of those already suffering from the various diseases is expected to increase if air pollution in the UK goes unchecked, says GlobalData, a leading data and analytics company. According to GlobalData’s reports: ‘PharmaPoint: Asthma’ states that the prevalence of asthma in the UK hovers...

Regeneron’s supplemental biologics license application of Eylea for the treatment of diabetic retinopathy could slow its downfall, says GlobalData

Following Regeneron’s announcement that the FDA has accepted to review a supplemental biologics license application (sBLA) of Eylea for the treatment of diabetic retinopathy, Edit Kovalcsik, Managing Analyst at GlobalData, a leading data and analytics company, offers her view on the impact of this indication expansion on the Eylea market; “Regeneron’s Eylea (aflibercept), a vascular...

Things starting to look up at Teva after fremanezumab gets FDA nod, says GlobalData

Following Friday’s announcement that Teva’s prophylactic migraine treatment, fremanezumab, received FDA approval, Rahael Maladwala, Pharma Analyst at GlobalData, a leading data and analytics company, offers his view on why fortunes are starting to brighten for a company which has experienced its fair share of problems recently: ‘‘Teva will breathe a sigh of relief after the...

Syphilis will remain a global burden in the next decade with an estimated 1.2m incident cases by 2027

Syphilis continues to be a global disease burden with a high and growing number of new cases each year with an estimated 1.2m incident cases forecast by 2027 in the 16 major markets (16MM*), according to GlobalData, a leading data and analytics company.

Lactalis’s acquisition of Aspen’s infant formula division boosts its potential in Chinese market, says GlobalData

Following Lactalis’s €740m (US$860.1m) purchase of South African-based pharma giant Aspen’s infant formula division, Fiona Dyer, Consumer Analyst at GlobalData, a leading data and analytics company, offers her view: “After baby milk brands were tainted by a salmonella infection scandal earlier in the year, Lactalis is seeking to win over several-times-bitten Chinese consumers by acquiring...

Top 25 global pharmaceutical companies by market cap Q2 2018, researched by GlobalData

The performance highlights of the Top 25 publicly traded global pharmaceutical companies by Market Cap (Mcap) for the quarter ended June 30, 2018 (Q2) ), compared to the quarter ended March 31, 2018 (Q1), have been analyzed in the latest research from GlobalData, a leading data and analytics company. The completed analysis revealed a number...

Approval of Keytruda in Europe for first-line use with chemotherapy in lung cancer strengthens the use of PD-1 inhibitors as backbone therapy, says GlobalData

Following FDA approval in August, this week (wk comm 10th Sept) the European Commission (EC) also approved Merck Sharp & Dohme (MSD)’s PD-1 blocking antibody, Keytruda (pembrolizumab), for use as a first-line therapy in combination with Eli Lilly’s Alimta (pemetrexed) plus platinum chemotherapy, for patients with metastatic non-small cell lung cancer (NSCLC) who have no...

Acorda needs strong marketing strategy to maximize Inbrija’s potential, says GlobalData

Following the ruling that Acorda’s patents for Ampyra are invalid, Rahael Maladwala, Pharma Analyst at GlobalData, a leading data and analytics company, offers his view on the impact this will have on the company’s portfolio positioning: “Ampyra, approved for the treatment of multiple sclerosis (MS), has been the lead asset in Acorda’s portfolio for the...

Migraine becoming less of a headache but there are still unmet needs to address, says GlobalData

Whilst the prognosis for migraine patients has never looked brighter, there are still unmet needs to address says GlobalData a leading data and analytics company, as this years Migraine Awareness Week (2-9 Sept), sets out to educate the public about the condition and reduce the stigma for patients. According to GlobalData’s report, ‘PharmaPoint: Migraine –...

The sky is the limit for Novartis’ CAR-T therapy Kymriah after approval for NHS use in paediatric leukemia patients, says GlobalData

Following the announcement that the NHS have accepted the revolutionary new Novartis CAR-T therapy, Kymriah, for children with leukemia, Rahael Maladwala, Pharma Analyst at GlobalData, a leading data and analytics company, offers his view on how this will impact the oncology market: “There is significant hype behind this therapy, as it offers a personalised approach...

Evolus back in the Botox biosimilar race, says GlobalData

Following the announcement that the FDA have accepted Evolus’ BLA resubmission for their Botox biosimilar, Rahael Maladwala, Pharma Analyst at GlobalData, a leading data and analytics company, offers his view on what this could mean for pharma company: “Evolus had their previous BLA submission rejected by the FDA in May 2018 due to concerns over...

Merck & Co can expect strong sales of Doravirine-based Drugs after Double-Approval, but not Blockbuster Status, says GlobalData

Following the announcement that Merck & Co has been granted FDA approval for two HIV drugs, Delstrigo (doravirine / lamivudine / tenofovir disoproxil fumarate) and Pifeltro (doravirine), Thomas Moore, Senior Pharma Analyst at GlobalData, a leading data and analytics company, offers his view: ‘‘This approval comes at a good time for Merck & Co, which...

UK medical devices industry faces uncertain future as it struggles to accommodate regulatory change in the headwinds of Brexit, says GlobalData

For medical devices, Brexit is coming at an inopportune time says GlobalData, a leading data and analytics company. EU Directives are currently transitioning to a new Medical Devices Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR), which is already having a profound impact on the medical devices industry and on the availability of medical devices to...

Washington State developing drugs to combat nicotine addiction is a step in the right direction

Following the announcement that Washington State University are developing drugs to treat nicotine addiction, Rahael Maladwala, Pharma Analyst at GlobalData, a leading data and analytics company, offers his view on what this could mean for the addiction market and if this research could be used in other addiction indications: “Scientists at Washington State University recently...

BIOplus 2018 : Game-changing insights and the latest research on immune checkpoint inhibitors for cancer therapy from GlobalData’s Fern Barkalow

BIOplus 2018 which takes place in Seoul next month (September 6th – 7th), will reveal the latest global intelligence in biotech and healthcare developments, focusing on game-changing insights to help bio companies grow their business. Fern Barkalow, PhD, Healthcare Director of Oncology and Hematology at GlobalData will join a presentation panel on the subject of...

Government technical papers indicate UK will be forced to relinquish control of pharma regulations to Europe in case of a ‘No-deal’ Brexit

Following the publication by the UK government (Thursday 23 August 2018) of 24 technical papers covering the likely impact of a no-deal Brexit, including five papers covering the healthcare sector, the pharmaceuticals industry now has some guidance on how to prepare for this eventuality and to some extent greater certainty over what to expect after Britain leaves the EU.

One less hurdle for scientists to navigate as gene editing in animals is viewed positively by majority of the American public

Following the release of poll results from Pew Research Center regarding public opinion on gene editing in animals, Rahael Maladwala, Pharma Analyst at GlobalData, a leading data and analytics company, offers his view on how a good public perception of gene editing could remove barriers that have held back research in the past: “A recent...

Orilissa Endometriosis drug uptake will be restricted

Following the recent approval of AbbVie’s Orilissa (elagolix) by the FDA, the Institute for Clinical and Economic Review (ICER) highlighted uncertainties about the oral pain relief medication’s long-term safety and clinical benefits, as well as cost-effectiveness over available alternative treatments.

There has been a negative shift in Brexit sentiment in the UK healthcare sector, finds GlobalData

There has been a negative shift in sentiment in the way that members of the UK healthcare sector perceive Brexit, according to GlobalData, a leading data and analytics company. The company’s latest report: ‘Brexit and the Healthcare Industry’ found that in July 2018, 37% of those from the UK healthcare industry believed that the UK...

North Americans are the least informed about GDPR in Pharma

North Americans were the least likely to say that they feel informed about the requirements of the General Data Protection Regulation (GDPR) out of those surveyed in the global pharmaceuticals industry, according to GlobalData, a leading data and analytics company. The company’s latest report: ‘GDPR in the Healthcare Industry’ states that only 54% of North...

‘No Brexit’ is the preferred, but not the most likely outcome of Brexit for the Pharma industry

Reversal of the referendum result is indicated as the best outcome of Brexit for the healthcare industry out of those surveyed in the pharmaceuticals industry, according to GlobalData, a leading data and analytics company. The company’s latest report: ‘Brexit and the Healthcare Industry’ states that 48% of participants across the US, UK, and EU felt...

Virgin Care take advantage of creaking NHS as the company picks up £2bn worth of contracts in the last 5 years

Following the news that Virgin has been awarded up to £2bn worth of NHS contracts in the last five years,

GDPR has had a greater impact on R&D in healthcare compared to other industries

R&D departments in healthcare organisations have felt a significantly higher impact due to the General Data Protection Regulation (GDPR) than in other sectors, according to GlobalData, a leading data and analytics company. The company’s latest report: ‘GDPR in the Healthcare Industry’ finds that, whilst most business departments have been affected similarly regardless of which sector...

Merck and InnoCore collaboration could be a step forward for biologic drug delivery

Following today’s (Friday 3 August) announcement of Merck and InnoCore’s collaboration, Rahael Maladwala, Pharma Analyst at GlobalData, a leading data and analytics company, offers his view on what this might mean for biologic drug delivery: “One of the biggest environmental unmet needs in the pharmaceutical market is a lack of compliance. Whether this is due...

A dramatic shift in the treatment paradigm in lung cancer is on the horizon

As part of World Lung Cancer Day 2018, Volkan Gunduz, PhD, Senior Pharma Analyst at GlobalData, a leading data and analytics company, offers his view on the changing lung cancer treatment landscape: ”The lung cancer treatment landscape is currently undergoing a notable reduction in the clinical development of chemotherapies and a significant increase in the...

Launch of Aimovig signals the start of a boom in the European migraine market

Following the launch of Novartis’ anti-migraine drug, Aimovig, in Europe, Rahael Maladwala, Pharma Analyst at GlobalData, a leading data and analytics company, offers his view on the potential growth of the market: “The calcitonin gene-related peptide (CGRP) monoclonal antibody class has generated significant excitement among headache specialists since posting promising efficacy results in early stage...

Takeda will be looking to Shire’s drug pipeline to bolster future sales after disappointing Q1 results

Following the announcement of a significant dip in first-quarter operating profit for Takeda, Thomas Moore, Senior Pharma Analyst at GlobalData, a leading data and analytics company, offers his view on the company’s future: “Takeda’s first-quarter operating profits took a 49% hit year-on-year, and represent the weakest first quarter profit in the last three years. Looking...

Merck KGaA looking to become a key player in the multiple sclerosis market as the FDA accept Mavenclad for review

Following the announcement that the FDA have accepted Merck KGaA’s resubmitted application for Mavenclad, seven years after the original application, Rahael Maladwala, Pharma Analyst at GlobalData, a leading data and analytics company, offers his view on the company’s current progress: “Merck KGaA have placed themselves in a strong position in the multiple sclerosis market with...

The ‘Biosimilar Action Plan’ is another FDA move designed to chase value based pricing

On Wednesday (18 July) the FDA unveiled the ‘Biosimilar Action Plan’ (BAP), which aims to promote the development and accessibility of biosimilars in the US healthcare market. Rahael Maladwala, Pharma Analyst at GlobalData, a leading data and analytics company, offers his view on what this means for the price of branded biologic molecules: “We believe...

J&J’s HIV therapeutic Symtuza on track for US launch in 2018 after FDA approval

Following the news (Tuesday 17th July) that J&J’s HIV therapeutic, Symtuza, has been granted marketing approval by the FDA, Tom Moore, Senior Healthcare Analyst at GlobalData, a leading data and analytics company, offers his view: “This news puts J&J’s Symtuza on track to launch in the US later this year, where it is predicted to...

Personalized medication is becoming an increasing possibility for patients, due to the use of newly developed algorithms

A long sought after objective of healthcare is to ensure that each patient receives tailored treatment for their medical situation; and now, with the use of big data and newly developed algorithms this is starting to look like a genuine possibility for patients, says GlobalData, a leading data and analytics company. A study conducted at...

Positive Phase III results in high-risk patients expected to support FDA review process for Roche’s Xofluza

Following yesterday’s news (Tuesday 17th July) that Roche has announced positive top-line results from its Phase III trial for influenza drug, Xofluza, Tom Moore, Senior Healthcare Analyst at GlobalData, a leading data and analytics company, offers his view: “Xofluza is forecast to reach annual sales of $600m by 2024. Although the drug is on track...

As Amazon’s acquisition of PillPack sends shockwaves across the pharma industry, GlobalData publish their Top 25 Global Pharmaceutical Companies analysis by Market Cap

The prospect of Amazon entering the pharma industry with the acquisition of PillPack will be a troubling development for pharma executives around the globe.

Positive Phase II data for Eisai and Biogen’s BAN2401 supports Amyloid precursor protein as a therapeutic target for Alzheimer’s

Following today’s news (Friday 6 July) that Eisai and Biogen have achieved positive top-line results in their Phase 2 trial for BAN2401 in Alzheimer’s patients,

UK based pharma professionals not anticipating staff relocations after Brexit but EU and US colleagues not so sure

In a recent survey of global healthcare professionals into the impact of Brexit on the Pharma industry, most participants working for UK-headquartered companies did not expect staff relocation's because of Brexit.

Takeda chases after its largest deal yet

Takeda’s possible $65B takeover of Shire could be the largest deal value in pharma this year, says GlobalData a leading data and analytics company. This is the Japanese company’s fifth attempt at merging with Shire, clearly highlighting Takeda’s readiness for this move. Notably, this deal is significantly larger than Takeda’s acquisition of Millennium in 2008 (for $8.8B), Nycomed in 2011 (for $13.7B), and Ariad in 2017 (for $5.2B).

Top 25 Global Pharma Companies by Market Cap (end of 2017)

The performance highlights of the Top 25 publicly traded global Pharma companies for the year 2017 have been confirmed in the latest research from GlobalData, a leading data and analytics company. The completed analysis reveals a number of interesting insights. The pharma sector’s 2017 v 2016 year on year performance inevitably created a mixed picture,...

General surgery market is set to reach $21.6bn by 2024

The general surgery market is forecast to grow steadily moving into the next decade. The market was valued at $14.6 bn in 2017 and is expected to reach a value of $21.6 bn in 2024, increasing at a Compound Annual Growth Rate (CAGR) of 5.7%, according to according to GlobalData, a leading data and analytics company.

Late-stage CKD-induced comorbidity therapeutics market to reach $10.5bn by 2026

Sales for chronic kidney disease (CKD)-induced hyperparathyroidism (HPT), hyperphosphatemia (HP), and hyperkalemia (HK) therapeutics were estimated to be $4.2bn across the seven major markets (7MM*) in 2016. This is expected to grow to $10.5bn in 2026, at a Compound Annual Growth Rate (CAGR) of 9.5%, according to GlobalData, a leading data and analytics company.

Need for supportive care in oncology will increase during the next decade

The need for effective supportive care in oncology will increase in the next decade as patients continue to live longer and cancer progresses to become more like a chronic disease. This includes the need for chemotherapy-related conditions, as chemotherapy will remain the backbone of cancer therapy for the foreseeable future, observes GlobalData, a leading data and analytics company.

World Cancer Day: What will 2018 mean for cancer research and treatment?

The theme of this year’s World Cancer Day held on 4th February of “We can. I can.” aimed to reinforce the public message that all individuals and groups can play their part in reducing the global burden of cancer. Indeed in recent years many events have involved collaborations between traditional drug developers, cancer treatment professionals and those of varying disciplines. Examples include the IBM Watson supercomputer which is helping physicians make treatment decisions and the development of other databases such as ASCO’s CancerLinQ which assists oncologists in monitoring and analyzing patient data.

Melanoma sales are projected to rise to $5.5bn in 2026

The value of the melanoma market was estimated to be $3.3bn across the seven major markets (7MM*) in 2016. This is expected to grow to $5.5bn in 2026, at a Compound Annual Growth Rate (CAGR) of 5.3%, according to GlobalData, a leading data and analytics company.

Global glaucoma market to reach $3.8bn by 2026

The total glaucoma market was estimated to be $2.6bn across the seven major markets (7MM*) in 2016. This is expected to grow to $3.8bn in 2026, at a Compound Annual Growth Rate (CAGR) of 4.1%, according to GlobalData, a leading data and analytics company.

Multiple sclerosis disease-modifying therapies market to reach $25 billion by 2026

Sales for Multiple Sclerosis (MS) disease-modifying therapies (DMTs) were estimated to be $19.1 billion across the seven major markets (7MM*) in 2016. This is expected to grow to $25.3 billion in 2026, at a Compound Annual Growth Rate (CAGR) of 2.9%, according to GlobalData, a leading data and analytics company.

Singapore’s pharmaceutical market value to reach $1.15 billion by 2021

Singapore’s pharmaceutical market is expected to expand from $903 million in 2016 to $1.15 billion by 2021, according to GlobalData, a leading data and analytics company.

Flexion’s Zilretta poised to shakeup knee osteoarthritis marketplace

Flexion Therapeutics recently announced the FDA approval of Zilretta, (triamcinolone acetonide [TA] extended-release injectable suspension) for the treatment of pain associated with moderate-to-severe knee osteoarthritis (OA). This is a segment of the patient population that GlobalData, a leading data and analytics company, expects to significantly drive the value of the market over the next 10 years.

Gilead’s Kite Pharma acquisition leads GlobalData’s Q3 2017 deals analysis

A recent analysis by GlobalData, a leading data and analytics company, identified the top 10 pharma companies by deal value for quarter 3, in 2017, revealed a number of key insights.

The global negative pressure wound therapy market set to reach $1.3bn in 2024

The global negative pressure wound therapy (NPWT) market, valued at $1.2bn in 2017, is expanding at a Compound Annual Growth Rate (CAGR) of 2.1% and is forecast to reach $1.3bn in 2024, according to GlobalData, a leading data and analytics company. Disposable NPWT devices are expected to increase at a CAGR of 8.3% during the forecast period.

Melanoma to significantly increase in the US adult population

The diagnosed incident cases of melanoma of the skin in men and woman, ages 18 years and older in the *7MM, are forecast to increase from 165,651 cases in 2016 to 206,717 cases in 2026, at an Annual Growth Rate (AGR) of 2.48% according to GlobalData, a leading data and analytics company.

Venezuela’s emerging pharmaceutical markets threatened by economic and political turmoil

Venezuela is one of the emerging pharmaceutical markets in South America, with a major dependence on imports. However, economic and political turmoil along with inefficient patent laws and drug pricing policies are major barriers according to GlobalData, a leading data and analytics company.

Non-small cell lung cancer has largest number of clinical trials in Australia and Globally over the last 5 years

A recent analysis of clinical trial activity in Australia by GlobalData, a leading data and analytics company, revealed that 3,199 clinical trials across all diseases and phases took place in the country between January 01, 2012 and December 31, 2016. Non-small cell lung cancer had the largest number of clinical trials overall in Australia, a pattern reflected globally.

New clinical trials of monoclonal antibodies have grown 115% in the last ten years

New clinical trials of monoclonal antibodies (mAb), have grown 115% globally over the ten year period 2007–2016 according to GlobalData, a leading data and analytics company. The most prominent increase, 26%, occurred in 2015.

Crohn’s Disease diagnosed incident cases set to increase in the 7MM to 2026

The burden of diagnosed Crohn’s disease (CD) is expected to grow between 2016 and 2026 in the seven major markets (7MM) *. Epidemiologists from GlobalData, a leading data and analysis company, forecast an increase in the number of diagnosed incident cases, most notably in the US and Japan. The chart below presents the expected changes in the 7MM from 2016 to 2026.

Taiwan’s Pharmaceutical Market Value to Reach $2.44 billion in 2021

The pharmaceutical market in Taiwan is estimated to reach $2.44 billion in 2021, according to GlobalData, a recognized leader in providing business information and analytics.

Indonesian Pharmaceutical Market Value to Reach $10.11 billion by 2021

Indonesia’s pharmaceutical market is the largest market in the Association of Southeast Nations (ASEAN) and is expected to reach $10.11 billion by 2021, according to GlobalData, a recognized leader in providing business information and analytics.

Crohn’s disease market growth to 2026 fuelled by interleukin inhibitor and anti-integrin therapy launches

The global Crohn’s disease (CD) market valued at $9.2 billion in 2016 is set to reach $13.4 billion by 2026, a Compound Annual Growth Rate (CAGR) of 3.8%, across the * 7MM according to GlobalData, a recognized leader in providing business information and analytics.

Alzheimer’s disease market set for double-digit growth with forecast sales of $14.8Bn by 2026

The global Alzheimer’s Disease (AD) market worth $2.9Bn in 2016 is set to reach $14.8Bn, rising at a Compound Annual Growth Rate (CAGR) of 17.5%, across the * 7MM by 2026 according to GlobalData, a recognized leader in providing business information and analytics.

Russia’s Pharmaceutical Market to Reach $36.61 billion by 2021

Russia’s pharmaceutical market is one of the fastest growing in the world and is expected to reach $36.61 billion by 2021, according to GlobalData, a recognized leader in providing business information and analytics.

Osteoarthritis 7MM market set to be worth $3.5 billion by 2026

The Osteoarthritis (OA) market is expected to increase from $1.6 billion in 2016 to $3.5 billion by 2026 in the seven major markets, * 7MM at a compound annual growth rate (CAGR) of 8.1%, according to GlobalData, a recognized leader in providing business information and analytics.

Global migraine market set to be worth $8.7 Billion by 2026

Global migraine sales are expected to grow to $8.7 billion by 2026, at a Compound Annual Growth Rate (CAGR) of 10.3% across the seven major markets * 7MM, according to GlobalData, a recognized leader in providing business information and analytics. The US will continue to dominate the market with a 77% share of total sales by 2026 followed by Germany (5.6%) and Italy (5.2%).

Healthcare-Associated Gram-Negative market to be worth $3.6 billion by 2026

The global marketplace for healthcare-associated infections (HAIs) caused by Gram-negative bacteria across the seven major pharmaceutical markets * (7MM) is projected to exceed $3.6 billion in sales by 2026, at a Compound Annual Growth Rate (CAGR) of 10.8% from 2016–2026, according to GlobalData, a recognized leader in providing business information and analytics.

Sepsis & septic shock market to be worth $5.9 billion by 2026

The sepsis and septic shock space across the seven major pharmaceutical markets (7MM) of the US, 5EU (France, Germany, Italy, Spain, and the UK), and Japan is set to grow from $2.8 billion in 2016 to $5.9 billion by 2026, representing a compound annual growth rate (CAGR) of 7.9%, according to GlobalData, a recognized leader in providing business information and analytics.

Nephrology and Urology Devices market growth predictions drive $57 billion investment

The latest report on the Nephrology and Urology Devices market from GlobalData, a recognized leader in providing business information and analytics, has highlighted how an explosion in diabetes and hypertension combined with aging populations is driving investment to meet patient needs. Leading companies in this field, principally from Europe and North America, have invested over $42 billion in mergers and acquisitions and nearly $15 billion in capital raisings over the last 3 years.

Global Clostridium difficile infections market to approach $1.7 billion by 2026

The Clostridium difficile infections (CDIs) space across the seven major markets of the US, France, Germany, Italy, Spain, the UK and Japan, is set to grow from just under $630 million in 2016 to almost $1.7 billion by 2026, representing a compound annual growth rate of 10.2%, according to GlobalData, a recognized leader in providing business information and analytics.

Hemophilia A and B market to welcome newcomers as established companies fall behind

The hemophilia A and B market, which is set to approach $8 billion by 2026, will see a substantial number of newcomers capture market share from established companies, according to GlobalData, a recognized leader in providing business information and analytics.

Asia-Pacific pedicle screw-based dynamic stabilization systems market to surpass $19 million by 2023

The pedicle screw-based dynamic stabilization systems space across the seven major Asia-Pacific (APAC) markets of Australia, China, India, Japan, New Zealand, South Korea and Taiwan, is set to rise from $12.5 million in 2016 to $19.2 million by 2023, representing a compound annual growth rate (CAGR) of 6.3%, according to GlobalData, a recognized leader in providing business information and analytics.

Hemophilia A and B market to approach $8 billion by 2026

The combined market value for hemophilia A and B across the seven major countries of the US, France, Germany, Italy, Spain, the UK and Japan is set to rise from $6.7 billion in 2016 to almost $8.0 billion in 2026, representing a compound annual growth rate of 1.8%, according to GlobalData, a recognized leader in providing business information and analytics.

Asia-Pacific drug delivery devices market set to leave North America behind by 2026

The drug delivery devices market in North America (United States, Canada and Mexico), which comprises approximate 50% of the global market, grew at a compound average growth rate (CAGR) of 2.6% from 2010 to 2016. However, the Asia-Pacific (APAC) region showed a highest growth with a CAGR of 3.4% during the same period, according to GlobalData, a recognized leader in providing business information and analytics.

Brazil’s highly attractive pharmaceutical market to approach $30 billion by 2021

The Brazilian pharmaceutical market is set to grow from $25.3 billion in 2016 to $29.9 billion in 2021, representing a compound annual growth rate of 3.5%, according to GlobalData, a recognized leader in providing business information and analytics.

Singapore’s pharmaceutical market set to break $1 billion mark by 2019

The pharmaceutical market in Singapore is set to rise from $948 million in 2017 to around $1.2 billion in 2021, and will first exceed the $1 billion mark in 2019, according to GlobalData, a recognized leader in providing business information and analytics.

Venous thromboembolism (VTE) market will see strong growth to 2026, hitting $2.85 billion

The venous thromboembolism (VTE) space across the seven major markets of the US, France, Germany, Italy, Spain, the UK, and Japan, is set to rise from $1.95 billion in 2016 to around $2.85 billion by 2026, representing a strong compound annual growth rate (CAGR) of 3.87%, according to GlobalData, a recognized leader in providing business information and analytics.

North America elbow replacement market to hit $29.5 million by 2023

The North American elbow replacement market, which covers Canada, Mexico, and the US, is set to grow from $23 million in 2016 to around $29.5 million by 2023, representing a compound annual growth rate (CAGR) of 3.6%, according to GlobalData, a recognized leader in providing business information and analytics.

request a demo

Make better and more timely decisions thanks to our unique data, expert analysis and innovative solutions delivered through a single platform.

Request a demo